MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Pfizer

Suletud

SektorTervishoid

22.8 1.83

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

22.23

Max

22.85

Põhinäitajad

By Trading Economics

Sissetulek

-4.1B

411M

Müük

63M

18B

P/E

Sektori keskmine

15.631

57.333

Aktsiakasum

0.63

Dividenditootlus

7.8

Kasumimarginaal

2.314

Töötajad

81,000

EBITDA

-4.3B

2.5B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+22.04% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

7.80%

2.63%

Järgmine tulemuste avaldamine

29. apr 2025

Järgmine dividendimakse kuupäev

13. juuni 2025

Järgmine aktsia dividendi kuupäev (ex-date)

9. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-26B

126B

Eelmine avamishind

20.97

Eelmine sulgemishind

22.8

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Pfizer Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. apr 2025, 11:09 UTC

Suurimad hinnamuutused turgudel

Pfizer Shares Slip After Company Scraps Weight-Loss Pill

9. apr 2025, 18:18 UTC

Suurimad hinnamuutused turgudel

Pharma Shares Reverse Losses After Tariff Pause

9. apr 2025, 09:39 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

19. märts 2025, 07:34 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sells Remaining 7.3% Haleon Shareholding for $3.25 Billion

18. märts 2025, 17:26 UTC

Omandamised, ülevõtmised, äriostud

Pfizer to Dispose of Remaining Shareholding in Haleon

14. apr 2025, 14:36 UTC

Peamised uudised

Pfizer Halts Development of Weight-Loss Pill -- Update

14. apr 2025, 14:14 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk

14. apr 2025, 10:45 UTC

Peamised uudised

Pfizer Halts Development of Weight-Loss Pill -- WSJ

8. apr 2025, 21:26 UTC

Tulu

Pfizer Stock's Fall to '97 Level Lifts Yield Near 8%. Dividend Looks Safe. -- Barrons.com

26. märts 2025, 22:29 UTC

Peamised uudised

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- 2nd Update

26. märts 2025, 19:19 UTC

Peamised uudised

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- Update

26. märts 2025, 17:39 UTC

Peamised uudised

U.S. Prosecutors Probe Tip About Timing of Pfizer Vaccine -- WSJ

18. märts 2025, 16:58 UTC

Omandamised, ülevõtmised, äriostud

Haleon Intends to Cancel Purchased Ordinary Shares

18. märts 2025, 16:57 UTC

Omandamised, ülevõtmised, äriostud

Citigroup: Off-Market Transaction Will Close at Same Time as or Following Settlement of Offering

18. märts 2025, 16:56 UTC

Omandamised, ülevõtmised, äriostud

Citigroup: Off-Market Purchase Worth Approx GBP170M in Ordinary Shares

18. märts 2025, 16:56 UTC

Omandamised, ülevõtmised, äriostud

Citigroup: Haleon Agreed to Carry out Off-Market Purchase From Pfizer

18. märts 2025, 16:52 UTC

Omandamised, ülevõtmised, äriostud

Haleon Takes Note of Announcement

18. märts 2025, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Citigroup: Haleon Won't Receive Any Net Proceeds From Offering

18. märts 2025, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Citigroup: This Is Subject to Customary Closing Conditions

18. märts 2025, 16:50 UTC

Omandamised, ülevõtmised, äriostud

Citigroup: Pfizer Will Receive All of Net Proceeds From Offering

18. märts 2025, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Citigroup: Bookbuilding Period May Close at Any Time on Short Notice

18. märts 2025, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Citigroup: Bookbuilding Period Will Commence Immediately

18. märts 2025, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Citigroup: Price Per Sale Share to Be Determined Through Accelerated Bookbuilding Process

18. märts 2025, 16:48 UTC

Omandamised, ülevõtmised, äriostud

Citigroup: Pfizer Intends to Sell Ordinary Shares to Institutional Investors

18. märts 2025, 16:47 UTC

Omandamised, ülevõtmised, äriostud

Citigroup:: Amount Is Pfizer's Entire Residual Shareholding in Haleon

18. märts 2025, 16:47 UTC

Omandamised, ülevõtmised, äriostud

Citigroup: This Represents Approx 7.3% Stake in Haleon

18. märts 2025, 16:46 UTC

Omandamised, ülevõtmised, äriostud

Citigroup: Pfizer Intends to Sell Approx 662M Ordinary Shares in Haleon

17. märts 2025, 09:00 UTC

Peamised uudised

Pfizer Has a New Playbook for Reviving Sales -- And It's Starting to Pay Off -- WSJ

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

14. veebr 2025, 11:38 UTC

Peamised uudised
Tulu

Moderna's Results Reaffirm a Grim Picture for Vaccine Maker -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Pfizer Prognoos

Hinnasiht

By TipRanks

22.04% tõus

12 kuu keskmine prognoos

Keskmine 27.8 USD  22.04%

Kõrge 32 USD

Madal 23 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Pfizer 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

17 ratings

5

Osta

12

Hoia

0

Müü

Tehniline skoor

By Trading Central

22.12 / 23.055Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Very Strong Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.